

For Research Use Only
Not for use in diagnostic procedure or decisions

Lunit SCOPE[®] uIHC

Universal Immunohistochemistry Quantification

Advance your IHC biomarker strategy with digital pathology X AI analysis

Applications

CDx development for next-gen IHC biomarkers

Drug target insights with high membrane and tumor specificity


Advanced and efficient IHC biomarker analysis for translational research

Description


- Artificial Intelligence (AI)-based digital pathology image analysis software
- Access any target across multiple cancer types
- Trained and tuned on broad dataset:
 - Over 6k WSIs
 - 18 types of IHC stains
 - Various cancers with more than 20 primary origins

Features

Continuous staining intensity quantification (0-100%) for each cell and location



Subcellular localization of target expression (membrane, cytoplasm, nucleus)




Cell type identification: Tumor cell, Lymphocyte, Macrophage, and Other Cell


Total Cells	Cell counts
Positive Tumor Cells	NNN_ (0-100%)
Negative Tumor Cells	NNN_ (0-100%)
Positive Lymphocyte	NNN_ (0-100%)
Negative Lymphocyte	NNN_ (0-100%)
Positive Macrophage	NNN_ (0-100%)
Negative Macrophage	NNN_ (0-100%)
Positive Other Cell	NNN_ (0-100%)
Negative Other Cell	NNN_ (0-100%)

Pioneering AI-Driven Biomarker Strategy Across Drug Development Phases

CDx development for next-gen IHC biomarkers



Drug target discovery



ASCO 2025 Artificial Intelligence(AI)-powered evaluation of protein drug-targetability through subcellular-level expression profiling from immunohistochemistry (IHC) images

Advanced and efficient IHC biomarker analysis for translational research

Lunit SCOPE uIHC analysis examples	Example targets (non-exhaustive)	
Subcellular target expression pattern	Staining (Antibodies)	TPS classification performance (accuracy)
Target prevalence	TROP2	94%
Intratumoral heterogeneity of target expression	MET	96%
Spatial distribution of targets	Claudin 18.2	94%
Detection of ultra-low expression	DLL3	100%
Multiplex IHC / IF or monoplex	HER3	94%
Precise determination of cut-off	FGFR2	81%
Cell type identification	E-Cadherin	90%
... and more	and many more targets	...

Reference: data on file

Versatility and end-to-end CDx capabilities

- | | |
|--|---|
| <p>Pan-tumor application</p> <ul style="list-style-type: none"> IHC trained, tuned, and validated across broad tissue types <p>Scanner compatibility</p> <ul style="list-style-type: none"> Compatible file types include Leica (.svs), Philips (.iSyntax, .tiff), 3D Histech (.mrxs), Hamamatsu (.ndpi) and other scanners at x40 magnification | <p>Regulatory & QMS track record</p> <ul style="list-style-type: none"> 3 Lunit SaMDs registered globally ISO 13485, US FDA 21 CFR Part 820, MDSAP <p>Scalable deployment</p> <ul style="list-style-type: none"> Digital pathology platforms & CRO partners Global commercial footprint |
|--|---|